Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients

Clinical Breast Cancer

Volumn 3, Issue 2, 2002, Pages 138-146

  Borstnar, S ^a   Vrhovec, I ^a   Svetic, B ^a   Cufer, T ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Plasminogen activator inhibitor 1; Plasminogen activator inhibitor 2; Prognosis; Urokinase type plasminogen receptor

Indexed keywords

HORMONE RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; TUMOR EXTRACT; UROKINASE; UROKINASE RECEPTOR;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER INVASION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PREDICTION; PROGNOSIS; PROTEIN LOCALIZATION; STATISTICAL SIGNIFICANCE;

EID: 0036348199     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2002.n.018     Document Type: Article

References (45)

1. Tamoxifen for early breast cancer: An overview of the randomised trials
2. Polychemotherapy for early breast cancer: An overview of the randomised trials
3. Angiogenesis and tumor metastasis
4. Tumor-associated proteases
5. The urokinase/urokinase-receptor system and cancer invasion
6. The urokinase-type plasminogen activator system in cancer metastasis: A review
7. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy
8. Binding of single-chain prourokinase to the urokinase receptor of human U937 cells
9. Plasminogen activators, tissue degradation, and cancer
10. Plasminogen activator inhibitors: Hormonally regulated serpins
11. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report
12. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer
13. Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer
14. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer
15. Multiparametric prognostic evaluation of biological factors in primary breast cancer
16. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1
17. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer
18. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis
19. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas
20. Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay
21. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer
22. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients
23. Prognostic impact of tumor biological factors on survival in node-negative breast cancer
24. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells
25. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
26. Novel methods for the determination of the angiogenic activity of human tumors
27. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients
28. Plasminogen activator inhibitor type 2 in breast cancer
29. Plasminogen activator inhibitor-2: Prognostic relevance in 1012 patients with primary breast cancer
30. Prognostic relevance of urokinase plasminogen activator and its inhibitors in patients with breast cancer
31. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients
32. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer
33. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer
34. Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours
35. Grading of invasive carcinoma of the breast
36. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts
37. Nonparametric estimation from incomplete observations
38. Regression models and life-tables
39. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients
40. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse
41. Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up
42. Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L
43. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1
44. Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence
45. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy